New privacy regulations along with new sets of guidelines in relation to the principle of “privacy by design” require thorough implementation in a company’s terms and conditions, reporting, and elsewhere. A secure communication management framework, such as the e-ID concept, is needed to comply with EU regulatory requirements, for example.
As automation propels big data, we help our clients develop effective solutions for protecting and managing information assets and complying with data protection law, including the preparation of expert opinions regarding data protection issues, drafting data protection guidelines, assisting with the appointment of data protection supervisors, and settling data protection issues in connection with compliance investigations.
Cyber threats are a growing concern for manufacturers of all sizes. Most manufacturers are critical infrastructure organizations with automated processes, intellectual property, and other sensitive information that may be vulnerable to cyber attacks. We help manufacturers prevent and deter attacks, pursue perpetrators, and mitigate risk and loss. Our team includes members with extensive experience in public policy, cyberforensic investigations, Internet tracking, rapid response, and insurance coverage.
Following earlier announcements as to the efficacy of vaccine trials by pharmaceutical companies Pfizer, Inc. (Pfizer) and Moderna, Inc. on November 20, 2020, Pfizer and BioNTech submitted applications for emergency use authorization to the U.S. Food and Drug Administration (FDA) for their COVID-19 vaccinations.
The Australian Government has announced a number of changes to its migration policies in September in response to the ongoing COVID-19 pandemic. This alert collates some of the recently announced changes that are most relevant to employers in Australia.
On 7 January 2021, the U.S. Equal Employment Opportunity Commission (EEOC) proposed two new rules designed to clarify the scope of incentives that employers may offer employees as part of a wellness program without violating the Americans with Disabilities Act (ADA) or Genetic Information Nondiscrimination Act (GINA).
On 23 December 2020, Judge Catherine Blake of the U.S. District Court for the District of Maryland granted the Pharmaceutical Research and Manufacturers of America (PhRMA) a 14-day nationwide temporary restraining order, preventing the Centers for Medicare and Medicaid Services (CMS) from implementing and enforcing its Most Favored Nation (MFN) interim final rule (MFN Rule) scheduled to take effect on 1 January 2021.
We welcome your email, but please understand that if you are not already a client of K&L Gates LLP, we cannot represent you until we confirm that doing so would not create a conflict of interest and is otherwise consistent with the policies of our firm. Accordingly, please do not include any confidential information until we verify that the firm is in a position to represent you and our engagement is confirmed in a letter. Prior to that time, there is no assurance that information you send us will be maintained as confidential. Thank you for your consideration.
